Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Integral Diagnostics stock price, quote, forecast and news

IDX.AX
AU000000IDX2

Price

2.58
Today +/-
-0.01
Today %
-0.34 %
P

Integral Diagnostics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Integral Diagnostics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Integral Diagnostics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Integral Diagnostics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Integral Diagnostics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Integral Diagnostics Stock Price History

DateIntegral Diagnostics Price
9/6/20242.58 undefined
9/5/20242.59 undefined
9/4/20242.61 undefined
9/3/20242.60 undefined
9/2/20242.60 undefined
8/30/20242.59 undefined
8/29/20242.66 undefined
8/28/20242.61 undefined
8/27/20242.61 undefined
8/26/20242.58 undefined
8/23/20242.55 undefined
8/22/20242.56 undefined
8/21/20242.48 undefined
8/20/20242.48 undefined
8/19/20242.50 undefined
8/16/20242.49 undefined
8/15/20242.48 undefined
8/14/20242.48 undefined
8/13/20242.48 undefined
8/12/20242.50 undefined
8/9/20242.49 undefined

Integral Diagnostics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Integral Diagnostics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Integral Diagnostics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Integral Diagnostics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Integral Diagnostics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Integral Diagnostics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Integral Diagnostics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Integral Diagnostics’s growth potential.

Integral Diagnostics Revenue, EBIT and net profit per share

DateIntegral Diagnostics RevenueIntegral Diagnostics EBITIntegral Diagnostics Net Income
2029e680.21 M undefined113.53 M undefined65.23 M undefined
2028e602.92 M undefined83.52 M undefined51.93 M undefined
2027e569.11 M undefined77.61 M undefined44.42 M undefined
2026e585.74 M undefined74.13 M undefined32.44 M undefined
2025e538.53 M undefined61.5 M undefined25.69 M undefined
2024e476.35 M undefined47.55 M undefined17.53 M undefined
2023440.79 M undefined39.83 M undefined25.04 M undefined
2022360.93 M undefined38.62 M undefined14.6 M undefined
2021350.7 M undefined56.07 M undefined31.27 M undefined
2020275.57 M undefined48.67 M undefined23.03 M undefined
2019232.39 M undefined37.87 M undefined20.98 M undefined
2018189.73 M undefined28.64 M undefined15.08 M undefined
2017180.1 M undefined23.87 M undefined15.48 M undefined
2016168.03 M undefined26.59 M undefined11.39 M undefined
2015151.4 M undefined25.11 M undefined4.5 M undefined
201460.6 M undefined10.5 M undefined6.1 M undefined
201351 M undefined10.3 M undefined4.9 M undefined

Integral Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
5160151168180189232275350360440476538585569602680
-17.65151.6711.267.145.0022.7518.5327.272.8622.228.1813.038.74-2.745.8012.96
96.0895.0094.0494.6495.0095.7795.2695.6495.1494.7295.23------
4957142159171181221263333341419000000
10102526232837485638394761747783113
19.6116.6716.5615.4812.7814.8115.9517.4516.0010.568.869.8711.3412.6513.5313.7916.62
4641115152023311425172532445165
-50.00-33.33175.0036.36-33.3315.0034.78-54.8478.57-32.0047.0628.0037.5015.9127.45
-----------------
-----------------
146.7146.7146.73143.06149.57149.84162.87189.43202.99211.87235.8000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Integral Diagnostics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Integral Diagnostics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2014201520162017201820192020202120222023
                   
6.79.6423.6624.2720.8421.2658.3762.2123.1933.86
3.95.095.886.095.629.6911.9318.3220.7323.59
00.230.410.3100.580.030.023.590.29
0.100.330.390.350.3910.911.261.85
0.91.491.662.213.521.915.130.85.23.16
11.616.4531.9533.2730.3333.8376.4682.25153.9862.74
17.937.9646.6350.5254.0870.78189.58211.49231.13282.46
00000009915915
00000001.584.922.38
2.38.678.027.537.1618.1427.2528.9428.0330.3
11.389.789.796.3996.39184.11280.02315.79352.46444.48
1.13.264.82.687.587.813.6116.3417.2519.03
32.6139.59149.16157.12165.2280.83510.45574.23633.95778.65
44.2156.04181.11190.39195.53314.67586.91656.48787.94841.39
                   
2.550.7482.7683.8783.43109.51207.44219.22322.54333.28
0000000000
3.9-2.099.1714.51025.6129.8644.6535.7549.8
00000-7.9-8.97-9.13-11.05-10.03
0000000000
6.448.6691.9398.3793.42127.22228.33254.74347.24373.05
43.424.133.3212.114.764.624.758.6910.41
3.315.7715.785.02021.9630.1735.6337.4448.01
8.25.881.1110.6810.962.4218.6720.5516.667.58
0000000000
5.413.716.7611.512.828.9322.7916.9717.2116.67
20.938.7727.7930.5135.8938.0776.2477.98082.67
12.668.7461.7861.452.5130.12255.06291.38323.78348.41
00004.747.9511.5213.8314.2317.59
2.46.687.628.138.9711.3115.7617.0517.7617.3
1575.4269.469.5266.22149.38282.34322.26355.77383.3
35.9114.297.19100.03102.11187.45358.58400.16435.77465.96
42.3162.85189.12198.4195.53314.67586.91654.9783.02839.01
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Integral Diagnostics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Integral Diagnostics's financial health and stability.

Assets

Integral Diagnostics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Integral Diagnostics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Integral Diagnostics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Integral Diagnostics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (k)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
0000000311425
0000000393643
0000000-10-1
0-1000-3-53-4-2-5-3
00000001,000-2,000-9,000
0-3-3-2-2-6-8-10-10-13
-2-6-7-7-6-9-10-16-17-1
12172422263354693771
-1-1-17-11-11-18-25-20-27-43
-5-67-16-14-10-94-93-56-55-128
-4,000-66,0000-3,0001,000-76,000-67,000-36,000-27,000-84,000
0000000000
046-142-77423813-21
02733001731912
-3536-7-196175-781-31
--10.00-12.00----3.00--2.00-
-3-100-10-11-14-18-17-20-12
19404933361021141021311
11.0215.166.8311.0814.9415.2528.3749.319.3327.42
0000000000

Integral Diagnostics stock margins

The Integral Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Integral Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Integral Diagnostics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Integral Diagnostics's sales revenue. A higher gross margin percentage indicates that the Integral Diagnostics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Integral Diagnostics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Integral Diagnostics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Integral Diagnostics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Integral Diagnostics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Integral Diagnostics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Integral Diagnostics Margin History

Integral Diagnostics Gross marginIntegral Diagnostics Profit marginIntegral Diagnostics EBIT marginIntegral Diagnostics Profit margin
2029e95.23 %16.69 %9.59 %
2028e95.23 %13.85 %8.61 %
2027e95.23 %13.64 %7.8 %
2026e95.23 %12.66 %5.54 %
2025e95.23 %11.42 %4.77 %
2024e95.23 %9.98 %3.68 %
202395.23 %9.04 %5.68 %
202294.67 %10.7 %4.05 %
202195.15 %15.99 %8.92 %
202095.47 %17.66 %8.36 %
201995.51 %16.3 %9.03 %
201895.44 %15.09 %7.95 %
201795.09 %13.25 %8.6 %
201695.02 %15.82 %6.78 %
201594.25 %16.58 %2.97 %
201495.54 %17.33 %10.07 %
201396.08 %20.2 %9.61 %

Integral Diagnostics Stock Sales Revenue, EBIT, Earnings per Share

The Integral Diagnostics earnings per share therefore indicates how much revenue Integral Diagnostics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Integral Diagnostics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Integral Diagnostics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Integral Diagnostics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Integral Diagnostics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Integral Diagnostics Revenue, EBIT and net profit per share

DateIntegral Diagnostics Sales per ShareIntegral Diagnostics EBIT per shareIntegral Diagnostics Earnings per Share
2029e2.91 undefined0 undefined0.28 undefined
2028e2.58 undefined0 undefined0.22 undefined
2027e2.43 undefined0 undefined0.19 undefined
2026e2.5 undefined0 undefined0.14 undefined
2025e2.3 undefined0 undefined0.11 undefined
2024e2.04 undefined0 undefined0.07 undefined
20231.87 undefined0.17 undefined0.11 undefined
20221.7 undefined0.18 undefined0.07 undefined
20211.73 undefined0.28 undefined0.15 undefined
20201.45 undefined0.26 undefined0.12 undefined
20191.43 undefined0.23 undefined0.13 undefined
20181.27 undefined0.19 undefined0.1 undefined
20171.2 undefined0.16 undefined0.1 undefined
20161.17 undefined0.19 undefined0.08 undefined
20151.03 undefined0.17 undefined0.03 undefined
20140.41 undefined0.07 undefined0.04 undefined
20130.35 undefined0.07 undefined0.03 undefined

Integral Diagnostics business model

Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future. Integral Diagnostics is one of the most popular companies on Eulerpool.com.

Integral Diagnostics SWOT Analysis

Strengths

Integral Diagnostics Ltd has several notable strengths that contribute to its success in the healthcare industry. Firstly, the company has an extensive network of medical imaging centers, allowing it to reach a wide customer base. This allows for increased market penetration and revenue generation. Additionally, Integral Diagnostics has a strong reputation for providing high-quality diagnostic services, which enhances its competitive advantage. The company also boasts a team of skilled and experienced medical professionals who provide accurate and reliable diagnoses, further solidifying its position in the market.

Despite its strengths, Integral Diagnostics Ltd faces several weaknesses that it needs to address. One weakness is the company's dependency on Medicare reimbursement rates for a significant portion of its revenue. This exposes the business to potential changes in government policies and regulations, which could negatively impact its financial performance. Another weakness is the limited geographical presence of Integral Diagnostics, primarily operating in Australia. This reduces its ability to capitalize on international market opportunities and diversify its revenue streams.

Integral Diagnostics Ltd has identified several opportunities for future growth. With the increasing demand for medical imaging services globally, the company can expand its operations internationally to tap into new markets. By leveraging advancements in technology, such as artificial intelligence and telemedicine, Integral Diagnostics can enhance its service offerings and improve efficiency. Furthermore, partnerships and collaborations with healthcare providers can lead to mutually beneficial arrangements and provide access to a larger patient population.

The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.

Weaknesses

Despite its strengths, Integral Diagnostics Ltd faces several weaknesses that it needs to address. One weakness is the company's dependency on Medicare reimbursement rates for a significant portion of its revenue. This exposes the business to potential changes in government policies and regulations, which could negatively impact its financial performance. Another weakness is the limited geographical presence of Integral Diagnostics, primarily operating in Australia. This reduces its ability to capitalize on international market opportunities and diversify its revenue streams.

Integral Diagnostics Ltd has identified several opportunities for future growth. With the increasing demand for medical imaging services globally, the company can expand its operations internationally to tap into new markets. By leveraging advancements in technology, such as artificial intelligence and telemedicine, Integral Diagnostics can enhance its service offerings and improve efficiency. Furthermore, partnerships and collaborations with healthcare providers can lead to mutually beneficial arrangements and provide access to a larger patient population.

The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.

Opportunities

Integral Diagnostics Ltd has identified several opportunities for future growth. With the increasing demand for medical imaging services globally, the company can expand its operations internationally to tap into new markets. By leveraging advancements in technology, such as artificial intelligence and telemedicine, Integral Diagnostics can enhance its service offerings and improve efficiency. Furthermore, partnerships and collaborations with healthcare providers can lead to mutually beneficial arrangements and provide access to a larger patient population.

The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.

Threats

The healthcare industry poses various threats to Integral Diagnostics Ltd. One major threat is the potential disruption caused by new competitors entering the market with innovative diagnostic technologies or business models. This could challenge the company's market share and competitive position. Additionally, changes in healthcare policies and regulations, both domestically and internationally, could affect reimbursement rates and operational requirements, disrupting Integral Diagnostics' financial performance and operations. Lastly, economic downturns and declines in healthcare spending can impact the overall demand for medical imaging services, creating a threat to the company's revenue generation.

Integral Diagnostics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Integral Diagnostics historical P/E ratio, EBIT, and P/S ratio.

Integral Diagnostics shares outstanding

The number of shares was Integral Diagnostics in 2023 — This indicates how many shares 235.795 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Integral Diagnostics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Integral Diagnostics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Integral Diagnostics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Integral Diagnostics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Integral Diagnostics dividend history and estimates

In 2023, Integral Diagnostics paid a dividend amounting to 0.09 AUD. Dividend means that Integral Diagnostics distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Integral Diagnostics provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Integral Diagnostics’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Integral Diagnostics's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Integral Diagnostics Dividend History

DateIntegral Diagnostics Dividend
2029e0.08 undefined
2028e0.08 undefined
2027e0.08 undefined
2026e0.08 undefined
2025e0.08 undefined
2024e0.08 undefined
20230.09 undefined
20220.1 undefined
20210.18 undefined
20200.13 undefined
20190.14 undefined
20180.11 undefined
20170.1 undefined
20160.06 undefined

Integral Diagnostics dividend payout ratio

In 2023, Integral Diagnostics had a payout ratio of 123.26%. The payout ratio indicates the percentage of the company's profits that Integral Diagnostics distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Integral Diagnostics represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Integral Diagnostics could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Integral Diagnostics's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Integral Diagnostics Payout Ratio History

DateIntegral Diagnostics Payout ratio
2029e128.75 %
2028e129.56 %
2027e129.07 %
2026e127.62 %
2025e131.99 %
2024e127.61 %
2023123.26 %
2022145.1 %
2021114.47 %
2020110.21 %
2019108.51 %
2018110.13 %
201793.69 %
201669.61 %
2015123.26 %
2014123.26 %
2013123.26 %
Unfortunately, there are currently no price targets and forecasts available for Integral Diagnostics.

Integral Diagnostics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.05 0.05  (-8.16 %)2024 Q4
12/31/20230.04 0.03  (-18.16 %)2024 Q2
6/30/20230.05 0.04  (-18.56 %)2023 Q4
12/31/20220.05 0.03  (-36.9 %)2023 Q2
6/30/20220.04 0.04  (2.36 %)2022 Q4
12/31/20210.07 0.06  (-5.4 %)2022 Q2
6/30/20210.09 0.07  (-18.63 %)2021 Q4
12/31/20200.06 0.11  (79.53 %)2021 Q2
6/30/20200.08 0.09  (11.85 %)2020 Q4
12/31/20180.09 0.08  (-6.62 %)2019 Q2
1

Eulerpool ESG Scorecard© for the Integral Diagnostics stock

Eulerpool World ESG Rating (EESG©)

85/ 100

🌱 Environment

76

👫 Social

99

🏛️ Governance

79

Environment

Scope 1 - Direct Emissions
588.1
Scope 2 - Indirect emissions from purchased energy
9,109.5
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
9,697.6
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees75
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Integral Diagnostics list of shareholders

%
Name
Stocks
Change
Date
8.71 % Yarra Funds Management Limited20,362,7162,404,33612/14/2023
5.01 % Perennial Value Management Ltd.11,711,594-2,486,77311/9/2023
4.99 % Viburnum Funds Pty Ltd11,678,72911,678,72911/28/2023
4.72 % Norges Bank Investment Management (NBIM)11,047,787-1,735,67811/10/2023
2.20 % State Street Global Advisors Australia Ltd.5,154,7345,132,23112/5/2023
1.90 % The Vanguard Group, Inc.4,438,398-121,7223/31/2024
1.84 % HUB24 Ltd.4,309,344-553,9118/1/2023
1.48 % Commonwealth Superannuation Corporation3,469,0481,899,7238/1/2023
1.45 % New Imaging Pty. Ltd.3,389,04508/1/2023
1.41 % Vanguard Investments Australia Ltd.3,294,015-488,8602/29/2024
1
2
3
4
5
...
8

Most common questions regarding Integral Diagnostics

What values and corporate philosophy does Integral Diagnostics represent?

Integral Diagnostics Ltd represents values of excellence, innovation, and integrity. With a strong corporate philosophy emphasizing patient care and diagnostic accuracy, Integral Diagnostics aims to provide the highest quality medical imaging and radiology services. The company's commitment to advanced technology and continuous improvement ensures accurate diagnoses, timely results, and exceptional patient outcomes. By investing in cutting-edge equipment, fostering a collaborative environment, and prioritizing professional development, Integral Diagnostics maintains its status as a trusted provider in the medical imaging field. With a focus on patient-centric care, the company consistently delivers superior diagnostic services, making it a preferred choice for medical professionals and patients alike.

In which countries and regions is Integral Diagnostics primarily present?

Integral Diagnostics Ltd is primarily present in Australia and New Zealand.

What significant milestones has the company Integral Diagnostics achieved?

Integral Diagnostics Ltd has achieved several significant milestones since its establishment. The company has successfully expanded its services and reach, becoming one of the leading providers of radiology and nuclear medicine services in Australia and New Zealand. Integral Diagnostics Ltd has also demonstrated consistent growth and financial success over the years. Additionally, the company has made strategic acquisitions, such as Cape Radiology and Global Diagnostics, further strengthening its position in the market. Integral Diagnostics Ltd continues to invest in advanced technology and quality patient care, striving to deliver exceptional diagnostic imaging services to its customers.

What is the history and background of the company Integral Diagnostics?

Integral Diagnostics Ltd is a leading medical imaging and radiology service provider in Australia and New Zealand. Established in 2008, the company has quickly grown to become a trusted name in the healthcare industry. With a strong focus on delivering high-quality diagnostic services, Integral Diagnostics utilizes advanced imaging technologies to assist in the accurate detection and diagnosis of various medical conditions. The company prides itself on its team of expert radiologists and state-of-the-art facilities, ensuring patients receive the best possible care. Integral Diagnostics continues to expand its network of clinics, striving to make diagnostic services more accessible to patients across the region.

Who are the main competitors of Integral Diagnostics in the market?

The main competitors of Integral Diagnostics Ltd in the market include companies like Sonic Healthcare Ltd, Healius Ltd, and Capitol Health Ltd.

In which industries is Integral Diagnostics primarily active?

Integral Diagnostics Ltd is primarily active in the healthcare industry. With a focus on precision radiology, the company provides a broad range of diagnostic imaging services including X-rays, ultrasounds, CT scans, and more. Integral Diagnostics operates in various sectors within healthcare, including hospitals, medical centers, and specialty clinics. With their high-quality imaging equipment and expert radiologists, Integral Diagnostics plays a crucial role in assisting healthcare professionals in accurate and timely diagnoses. As a leading player in the healthcare industry, Integral Diagnostics Ltd continues to contribute to the advancement of medical imaging and patient care.

What is the business model of Integral Diagnostics?

The business model of Integral Diagnostics Ltd is focused on providing comprehensive diagnostic imaging services to the medical industry. They operate a network of medical imaging clinics across Australia, offering a wide range of imaging services such as MRI, CT, ultrasound, and X-ray scans. Integral Diagnostics aims to deliver high-quality radiology services, ensuring accurate and timely diagnosis for patients. Through their state-of-the-art facilities and experienced medical professionals, they aim to consistently meet the growing demand for advanced imaging services. Integral Diagnostics Ltd aims to enhance patient care and support healthcare providers in delivering effective treatment plans.

What is the P/E ratio of Integral Diagnostics 2024?

The Integral Diagnostics P/E ratio is 34.7.

What is the P/S ratio of Integral Diagnostics 2024?

The Integral Diagnostics P/S ratio is 1.28.

What is the AlleAktien quality score of Integral Diagnostics?

The AlleAktien quality score for Integral Diagnostics is 6/10.

What is the revenue of Integral Diagnostics 2024?

The expected Integral Diagnostics revenue is 476.35 M AUD.

How high is the profit of Integral Diagnostics 2024?

The expected Integral Diagnostics profit is 17.53 M AUD.

What is the business model of Integral Diagnostics

Integral Diagnostics Ltd is a leading Australian diagnostic company that offers medical imaging and pathology services. The company was founded in 1998 and has been listed on the Australian stock exchange since 2015. Integral Diagnostics' business model is based on providing high-quality diagnostic services needed by physicians and other healthcare providers to make accurate diagnoses and ensure the best possible treatment for their patients. Integral Diagnostics operates several business divisions, including radiology services, pathology services, and clinical trials. In the radiology field, the company offers a wide range of diagnostic imaging services, including X-rays, ultrasound, MRI, and CT scans. The company has over 50 radiology practices throughout Australia and a growing presence in New Zealand. The company also offers specialized radiology services such as oncology imaging and intervention, as well as training and workshops for medical staff. Integral Diagnostics also operates a pathology division, which offers a comprehensive range of pathology services including clinical chemistry, hematology, histopathology, and microbiological testing. Integral Diagnostics' pathology services are used for diagnosing diseases and monitoring patients undergoing treatment. In the pathology division, Integral Diagnostics operates 17 laboratories throughout Australia. In addition to radiology and pathology services, Integral Diagnostics also conducts clinical trials. The company provides support to medical researchers in conducting clinical trials and evaluating the effectiveness of new treatment methods. Integral Diagnostics' clinical trials cover a wide range of medical specialties, including oncology, cardiology, and neurology. Integral Diagnostics has a robust IT system that allows for the electronic transmission of patient data and images. The company also operates an online platform through which physicians and medical professionals can access their patient data and images. This facilitates information exchange among doctors and enables quicker diagnosis and treatment of patients. Integral Diagnostics' business model is based on providing high-quality and efficient diagnostic services. The products offered by Integral Diagnostics are essential tools for physicians and medical professionals to make accurate diagnoses and ensure the best possible treatment for patients. When it comes to search engine optimization (SEO), it is important to use relevant keywords that users enter when searching for medical diagnostic services. These may include keywords such as "radiology services," "pathology services," and "clinical trials." The text should also provide the reader with a clear overview of Integral Diagnostics' business model without being too promotional.

What is the Integral Diagnostics dividend?

Integral Diagnostics pays a dividend of 0.1 AUD distributed over payouts per year.

How often does Integral Diagnostics pay dividends?

The dividend cannot currently be calculated for Integral Diagnostics or the company does not pay out a dividend.

What is the Integral Diagnostics ISIN?

The ISIN of Integral Diagnostics is AU000000IDX2.

What is the Integral Diagnostics ticker?

The ticker of Integral Diagnostics is IDX.AX.

How much dividend does Integral Diagnostics pay?

Over the past 12 months, Integral Diagnostics paid a dividend of 0.09 AUD . This corresponds to a dividend yield of about 3.32 %. For the coming 12 months, Integral Diagnostics is expected to pay a dividend of 0.08 AUD.

What is the dividend yield of Integral Diagnostics?

The current dividend yield of Integral Diagnostics is 3.32 %.

When does Integral Diagnostics pay dividends?

Integral Diagnostics pays a quarterly dividend. This is distributed in the months of April, September, March, September.

How secure is the dividend of Integral Diagnostics?

Integral Diagnostics paid dividends every year for the past 14 years.

What is the dividend of Integral Diagnostics?

For the upcoming 12 months, dividends amounting to 0.08 AUD are expected. This corresponds to a dividend yield of 3.28 %.

In which sector is Integral Diagnostics located?

Integral Diagnostics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Integral Diagnostics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Integral Diagnostics from 10/3/2024 amounting to 0.047 AUD, you needed to have the stock in your portfolio before the ex-date on 8/30/2024.

When did Integral Diagnostics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Integral Diagnostics in the year 2023?

In the year 2023, Integral Diagnostics distributed 0.1 AUD as dividends.

In which currency does Integral Diagnostics pay out the dividend?

The dividends of Integral Diagnostics are distributed in AUD.

All fundamentals about Integral Diagnostics

Our stock analysis for Integral Diagnostics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Integral Diagnostics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.